Seattle, WA, United States
Seattle, WA, United States

Time filter

Source Type

"I am honored to join the Angiogenesis Foundation as an advisor," said Stott. "My journey as both an astronaut and mother have taught me that good health is essential to exploring the unknown and ensuring the best future for my family. I want to lend my voice to support science that is improving healthy living both on and off the planet. The Angiogenesis Foundation is a unique scientific organization that is driving innovations in health and I am thrilled to be a part of it." Nicole Stott is a retired NASA astronaut. Over the course of her 27-year career with NASA, she flew two spaceflight missions and spent 104 days living and working in space on both the Space Shuttle and the International Space Station (ISS). Stott's many accomplishments include performing a seven-hour spacewalk and being the first person to guide the space station's Canadarm2 robotic arm for the first track and capture of a visiting cargo vehicle. Stott was the last crew member to fly to and from their ISS mission on a Space Shuttle and she was a member of the crew of the final flight of the Space Shuttle Discovery, STS-133. Stott is also a NASA Aquanaut and holds the Women's World Record for saturation diving following her 18-day mission with the NEEMO9 crew on the Aquarius undersea habitat. She is now a full-time artist and SciArt education advocate who believes that sharing the perspective she was blessed to experience through spaceflight has the power to increase our appreciation of and obligation to care for our home planet and each other. The Angiogenesis Foundation is an independent 501(c)(3) third party scientific organization driving innovations in health promotion and disease prevention. For more than two decades, the Foundation has through its field catalyzed scientific breakthroughs and collaborated across disciplines from food and life sciences, precision health and genomics, biomarkers, microbiomics, preventative medicine, nutrition, and technology. The Foundation takes a systems-based approach to connect, analyze, and translate scientific data to improve health outcomes for people around the world. This work is igniting a paradigm shift in global health rooted in science-based health promotion and disease prevention. To learn more about the Angiogenesis Foundation, please visit Established in 1994, the Angiogenesis Foundation helps people lead healthier, longer lives through angiogenesis-based treatment and prevention. For more information, visit To view the original version on PR Newswire, visit:

News Article | April 28, 2017

NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2016: - Expansion of Nanobiotix clinical development program - six clinical trials running in seven indications-activities in relation to the market access of NBTX3, Nanobiotix' lead product, have impacted operating expenses as planned - Increase of revenues with a $1M milestone payment from PharmaEngine - Consolidation of the cash available at EUR 21.1M strengthened by the completion of a private placement executed in March 2016 Income statement 2016 2015 ---------------------------------------------------------------------- Total revenue EUR 5,421,613 4,015,229 ---------------------------------------------------------------------- Sales 1,558,101 265,543 License 1,075,372 183,893 Other sales 99,450 66,179 Services 383,279 15,471 ---------------------------------------------------------------------- Other revenue 3,863,512 3,749,686 Subsidies 98,095 199,838 Research Tax Credit 3,703,278 3,546,035 Other 62,139 3,814 Cost of sales -- -- R&D costs (16,915,243) (13,901,898) Selling, General and Administrative (SG&A) (8,370,208) (5,963,488) (Market Access, BD & other corporate costs) Costs associated with payments in shares (1,990,855) (1,291,491) ---------------------------------------------------------------------- Core operating loss (21,854,693) (17,141,647) ---------------------------------------------------------------------- Net Interest Income (*) 64,607 138,562 ---------------------------------------------------------------------- Core pre-tax loss (21,790,086) (17,003,084) ---------------------------------------------------------------------- Tax (90,425) -- ---------------------------------------------------------------------- Net Profit & Loss (21,880,511) (17,003,084) ---------------------------------------------------------------------- * Interest Income minus Interest Expenses Financial Review Total Revenue in 2016 amounts to EUR 5.4M vs. EUR 4.0M in 2015 mainly due to: - Sales revenue from PharmaEngine amount to EUR 1,558K (vs. EUR 265,5K in 2015), with (1) EUR 184K coming from the upfront payment received in 2012 and linearized on an annual basis (2) EUR 890K (US$ 1M) coming from a milestone payment triggered by the injection of the first patient in Nanobiotix' Soft Tissue Sarcoma (STS) pivotal phase, and (3) EUR 483K for re-invoicing of services and material; and - Other revenue of EUR 3,863.5K (vs. EUR 3,749.7K in 2015) mainly generated by the Research Tax Credit (CIR) and evolving in correlation with the level of R&D activities. Total Operating expenses reach EUR 27.3M in 2016 vs. EUR 21.2M in 2015: - R&D expenses at EUR 16.9M (+EUR 3M) to support the acceleration of clinical programs (EUR 7.2M), the manufacturing activities (EUR 3.5M) and the preclinical research developments (EUR 3.9M) - SG&A costs reached EUR 8.4M (+EUR 2.4M) mainly due to the ongoing support in market access and launch readiness (EUR 2.5M), Business Development activities (EUR 1,3M) and other corporate costs, in accordance with the group development plan - Cost associated with share based payment reached EUR 2.0M in 2016 (vs. EUR 1.3M in 2015) which proceeds to an accounting evaluation (non-cash expenses). Total consolidated Headcount reached 67 FTEs in 2016 vs. 60 FTEs in 2015 in line with the development of the company. Total loss after tax amounts to EUR -21,9M (vs. EUR -17,0M FYE 2015) in line with planned operations. FYE 2016 cash available amounts to EUR 21.1M as per expectations. In April 2017 the Company has completed a private placement of EUR 25.1M providing additional resources to support the group development. This operation has been the opportunity for Nanobiotix institutional shareholders to reinforce their position and to welcome new shareholders from US and EU. Post year-end events Recommendation to continue the Phase II/III study in Soft Tissue Sarcoma- In March 2017, Nanobiotix announced that the Independent Data Monitoring Committee (IDMC) recommended the continuation of the ongoing phase II/III trial of NBTXR3 in Soft Tissue Sarcoma ( study), based on the safety and efficacy data. The interim evaluation was based on an analysis of the results of two-thirds of the patients included in the Phase II/III study - 104 patients were analyzed out of a total of 156. The completion of recruitment is planned by the end of Q2 2017 and the full data is expected by the end of 2017. Presentation of NBTXR3 preclinical data- Nanobiotix announced in March 2017, the presentation of NBTXR3 preclinical studies demonstrating 1) the antitumor efficacy of NBTXR3 in five different in vivo human cancer models and 2) the antitumor efficacy of NBTXR3 in combination with chemotherapy, in both in vitro and in vivo studies. These data have been presented at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, D.C (April 1-5, 2017). Presentation of NBTXR3 clinical data- Nanobiotix announced in April 2017 the presentation of the Phase I/II data of Nanobiotix's European head and neck trial with NBTXR3 at the American Society of Clinical Oncology (ASCO) Annual Meeting in June. The Company also announced the expansion of Nanobiotix's Immuno-Oncology program into patients focused on the objective of turning cold tumors into hot tumors and will present the first clinical data from this program mid-year. Completion of a private placement of EUR 25,1M- To reinforce its development, Nanobiotix completed a EUR 25.1 million private placement in early April 2017, corresponding to 1,596,527 new shares, which have been placed with qualified institutional investors in the United States and Europe. The order book was well covered based on strong demand from new life sciences specialist and generalist investors as well as existing shareholders reinforcing their position. This private placement will be used for i) next clinical steps of the head and neck cancer program with NBTXR3, both in the U.S. and Europe, (ii) market preparations for NBTXR3's launch on the European market, (iii) expansion of Nanobiotix's Immuno-Oncology program into patients, and (iv) general corporate purposes. Governance- Beginning of 2017, Nanobiotix appointed Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer (COO) to oversee operations and product commercialization. Next financial press release: revenue for Q1 2017 on May 15, 2017. About NANOBIOTIX: Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration. NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix's Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company has filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3. The Company started in 2016 a new preclinical research program in Immuno-oncology with its lead product NBTXR3, which could have the potential to bring a new dimension to cancer immunotherapies. Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company Headquarter is based in Paris, France. Affiliate in Cambridge, United States. Contact: Nanobiotix Sarah Gaubert Director, Communications & Public Affairs +33 1 40 26 07 55 / Noel Kurdi Director, Investor Relations +1 646 241 4400 / Media relations France - Springbok Consultants Marina Rosoff +33 6 71 58 00 34 United States - RooneyPartners Marion Janic +1 212 223 4017 Disclaimer- This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the update of the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorite des Marches Financiers) under number D.16-0732-A01 on December 27, 2016 (a copy of which is available on and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country. At the moment NBTXR3 does not bear a CE mark and is not permitted to be placed on the market or put into service until NBTXR3 has obtained a CE mark.

A method of testing a target electronic device implemented in a configurable integrated circuit device includes receiving a baseline design for the target electronic device in a hardware description language, establishing a fault model for the particular configurable integrated circuit device, synthesizing the fault model in the hardware description language, embedding the synthesized fault model into the baseline design to create a modified baseline design in the hardware description language which enables one or more targeted signals to be selectively corrupted, creating a fault model enabled target device on the particular configurable integrated circuit device using the modified baseline design, performing a number of fault injection experiments on the fault model enabled target device, wherein each fault injection experiment includes causing at least one of the one or more targeted signals to be corrupted within the fault model enabled target device.

STS Inc | Date: 2011-07-29

An embodiment of a power supply includes an input node, a converter stage, and an outlet. The input node is operable to receive an input AC signal having peak portions and non-peak portions. The converter stage is operable to generate a DC power signal from the input AC signal and to cause a first current to be drawn from the input node during at least the non-peak portions of the input AC signal. And the outlet is operable to carry the DC power signal. For example, such a power supply may be installed in a facility such as a residence, office building, or manufacturing plant, or the facilitys existing power supply may be retrofitted, to provide one or more power outlets that each carry a respective power-factor-corrected (PFC) DC voltage. Because the outlet voltages are PFC voltages, the amount of wasted power dissipated in the facility power lines/wiring and in the main power lines from the power company may be significantly reduced, without requiring each piece of equipment (e.g., an appliance, machinery) that is wired/plugged into the outlets to have an onboard PFC. This savings in wasted power may provide a significant cost savings to both the facility owner (e.g., lower electric bill) and the power company (e.g., lower power-generation and grid costs), and the ability to use equipment lacking onboard PFCs may reduce the purchase price of the equipment.

A detection and indication system for use in a railway switch machine which utilizes one or more roller members which physically interact with a point detector bar coupled to one or more switch points to provide an indication of a point failure upon movement of the point detector bar a predetermined distance from an initial position. The system includes a mounting structure structured to be coupled to a housing of the switch machine and a first sensing device coupled to the mounting structure. The first sensing device is positioned and structured to detect movement of the point detector bar a second predetermined distance from the initial position, wherein the second predetermined distance is less than the first predetermined distance.

A method of adjusting one or more of braking parameters used in a braking function to control braking of a train includes determining an adjustment factor based on a joint stopping distance probability distribution, the joint stopping distance probability distribution representing the composite effect on stopping distance of a plurality of predetermined train characteristic parameters, each of the predetermined train characteristic parameters being variable, and applying the adjustment factor to each of the one or more of braking parameters. Also, a method of adjusting braking parameters that includes determining an adjustment factor based on a nominal value, a worst case limit value and a best case limit value of each of a plurality of predetermined train characteristic parameters, each of the predetermined train characteristic parameters being variable, and applying the adjustment factor to each of the one or more of braking parameters.

A railroad monitoring apparatus includes first and second diverse vital processing units, first and second current sensors configured to measure the current being provided to one or more signaling elements of an item of wayside signaling equipment, and means for measuring voltage levels being supplied to each of the signaling elements. The first processing unit receives a first current measurement from the first current sensor and the measured voltage levels, and the second vital processing unit receives a second current measurement from the second current sensor and the measured voltage levels. The vital processing units are each programmed to determine based on one or more of the first current measurement, the second current measurement and the measured voltage levels: (i) the state of the item of railroad wayside signaling equipment, (ii) failures within the item of railroad wayside signaling equipment, and (iii) failures within the monitoring apparatus itself.

STS Inc | Date: 2012-05-24

An electronic amplifier includes a configurable integrated circuit device structured to synthesize at least a first signal and a second signal, scale the first signal to create a scaled first signal and scale the second signal to create a scaled second signal, create a discrete time composite signal which comprises a summation of at least the scaled first signal and the scaled second signal, create a discrete time pulse width modulated signal based on the discrete time composite signal, and generate a number of control signals based on the discrete time pulse width modulated signal. The electronic amplifier also includes a power switching stage receiving the number of control signals from the configurable integrated circuit device, wherein the number of control signals are configured to control the power switching stage, and a low pass filter coupled to an output of the power switching stage.

A sequential monitoring system is for an interlocking logic system and a track circuit system including a plurality of track circuits. The sequential monitoring system includes an interface between the interlocking logic system and the track circuit system; and a processor structured to monitor a state of each of the track circuits, validate a sequence of state changes of the track circuits, and interrupt and correct invalid track circuit state indications between the track circuit system and the interlocking logic system. The interface normally passes inputs from the track circuit system to outputs to the interlocking logic system. When an out of sequence event occurs, the processor applies a quarantine to a minimum of three of the track circuits in a quarantined area, thereby inhibiting use of an unoccupied track circuit in the quarantined area.

STS Inc | Date: 2014-02-11

A method of controlling braking of a train that includes obtaining in an on-board computer of the train a brake propagation delay time (T_(d)), a brake build-up time (T) and a maximum brake rate (_(max)) for the train, and controlling braking of the train in the on-board computer by generating one or more braking signals for the train using T_(d), T and _(max). Also, a methods of determining for a train a profile velocity to a target position of a selected target, selecting a most restrictive target from among a plurality of targets for a train, and determining a plurality of braking parameters for a train having a train consist, wherein the parameters include a brake propagation delay time (T_(d)), a brake build-up time (T) and a maximum brake rate (_(max)).

Loading STS Inc collaborators
Loading STS Inc collaborators